Background: No study has assessed the possible involvement of endothelial nitric oxide synthase (eNOS) T-786C and G894T and G-protein b3 subunit (GNB3) C825T polymorphisms with susceptibility to diabetic vasculogenic erectile dysfunction (VED) in North African subjects. Objectives: Our aim was to evaluate the interaction and association between these gene polymorphisms and this disorder. Materials and methods: A total of 164 type 2 diabetes patients with VED diagnosed with penile color Doppler ultrasonography and 148 age-matched healthy volunteers were genotyped for the rs1799983 (G894T) and rs2070744 (T-786C) of the eNOS gene and the rs5443 (C825T) of the GNB3 gene using the PCR-RFLP method. Results: A significant association of the eNOS G894T (p = 0.005) and T-786C (p = 0.02) with altered susceptibility to VED was observed. The risk also holds for the G894T and T-786C eNOS gene polymorphisms when excluding patients with dyslipidemia and cardiovascular diseases (p = 1.7Á10 À4 and p = 3.2Á10 À5 , respectively). The univariate odds ratio associated with CC alleles of the eNOS
INTRODUCTION
Diabetes is a serious, chronic disease that leads to a number of short-and long-term health disorders, including microvascular and macrovascular complications. The mechanisms by which diabetic vascular complications develop are not fully established but include genetic influences. Previous case-control studies suggest that dysfunctional genes might play a critical role in the pathogenic pathway leading to diabetic nephropathy (Zhang et al., 2015) , retinopathy (Bazzaz et al., 2010) , and neuropathy (Shah et al., 2013) . The World Health Organization (WHO) considers diabetic erectile dysfunction (ED) as the most common vascular complication in men with diabetes (World Health Organization, 2017) . ED is defined as the consistent or recurrent inability of a man to attain and/or maintain penile erection sufficient for sexual activity (McCabe et al., 2016) . The pathophysiology of ED in diabetic men includes vascular and neurogenic causes, oxidative processes, endothelial dysfunction, and changes in the nitric oxide (NO) system (Ph e & Rouprêt, 2012) . However, recent candidate gene association studies suggest that human genetic variations could represent a potential supplementary risk factor in the pathogenesis of ED (Andersen et al., 2011; Lopushnyan & Chitaley, 2012) . Several epidemiological studies have been performed to identify candidate genes associated with ED (Andersen et al., 2011) . Polymorphisms of endothelial nitric oxide synthase (eNOS) and guanine nucleotide-binding proteins (GNB3) genes were associated with increased ED risk in diverse ethnic groups (Wang et al., 2010; Safarinejad et al., 2013; Gao et al., 2017) .
eNOS is one of the most studied candidate genes in the relaxation of penile corpus cavernosum smooth muscle pathway (Lopushnyan & Chitaley, 2012) . The eNOS gene was assigned to the 7q36 region (Marsden et al., 1993) . It contains 26 exons spanning approximately 21 kb of genomic DNA, encodes an mRNA of 4.052 nucleotides and a protein of 1.203 amino acids (133 kDa) (Marsden et al., 1993) . The eNOS glu298-to-asp mutation in exon 7 resulting from a G894T transversion is the only coding region variant identified in eNOS. The protein product of eNOS 894T is more susceptible to selective proteolytic cleavage in vascular tissues and endothelial cells (Tesauro et al., 2000) which could lead to reduced vascular NO generation. In addition, a study found evidence of three linked mutations in the 5-prime flanking region of the eNOS gene, among them a T-786C transition (Nakayama et al., 1999) . As assessed by luciferase reporter gene assays, the T-786C polymorphism resulted in a significant reduction of eNOS gene promoter activity and a decrease in serum NO concentration (Seckin et al., 2016) .
Heterotrimeric guanine nucleotide-binding proteins are a class of proteins composed of three subunits, a, b and c, that communicate signals from distinct superfamily of receptors to a wide range of intracellular signaling pathways including erectile function (Safarinejad et al., 2013) . The G-protein b3 subunit (GNB3 or GB3) gene is mapped to 12p13, consists of 12 exons, and encodes a peptide of 340 amino acids (Levine et al., 1990) . The GNB3 C825T polymorphism leads to the appearance of shortened form of Gb3, referred to as Gb3s, which appears to have increased activity (Kedzierska et al., 2006) . Multiple case-control studies have investigated the association between this polymorphism with ED (Lee et al., 2008; Eisenhardt et al., 2010; Safarinejad et al., 2013 ), yet it is not fully known how C825T polymorphism predisposes for ED. The proposed physiological mechanisms by which this polymorphism may be involved in ED are shown in Fig. 1 . Gb3s can increase intracellular calcium concentration by the activation of phospholipase C, thereby increasing the formation of inositol trisphosphate which in consequence can lead to the downregulation of penile vasomotor tone ( Fig. 1 ) (Kedzierska et al., 2006) . It was reported that the truncated splice variant Gb3s could activate the chain reaction associated with mitogen-activated protein kinases via the system of ras and raf protein kinases and the activation of phospholipase C (Fig. 1) (Rosskopf et al., 2003) . The mitogen-activated protein kinases are potent endogenous vasoconstrictors that can directly affect relaxation of vascular smooth muscle cells leading to impaired penile tumescence. Moreover, Gb3s inhibit the adenylyl cyclase leading to a decrease in cyclic adenosine monophosphate concentration in penile cavernosal cells and might account for a critical susceptibility of penile erection (Kedzierska et al., 2006) .
The possible interaction between GNB3 and eNOS activation has been recently consolidated. Two studies showed that G-protein bc subunits mediated activation of phosphatidylinositol 3-kinase and Akt to regulate eNOS and that eNOS can directly bind to the G-protein-coupled receptor kinaseinteracting protein 1 which stimulates NO production (Liu et al., 2003 (Liu et al., , 2012 (Liu et al., , 2014 . Gb3s may therefore lead to changes in eNOS function and impaired NO bioactivity (Fig. 1) . Further mechanistic in vitro studies are, however, needed to generate more reliable conclusions on cellular interactions between GNB3 and eNOS variants.
In genetic analysis, it is strongly recommended to consider a combination of polymorphisms to obtain more informative data. To our knowledge, there have been no studies about the associations between the eNOS T-786C and G894C gene polymorphisms and the GNB3 C825T variant with vasculogenic ED (VED) risk reported in North African subjects. In this work, we investigated the possible synergistic effects between these gene polymorphisms, VED and related risk factors in type 2 diabetes (T2D) Tunisian males.
METHODS

Subjects and study protocol
All subjects have been diagnosed with T2D as per WHO criteria completed a 5-item International Index of Erectile Function (IIEF) questionnaire (Rosen et al., 2002) . IIEF is a diagnostic tool used for the screening of erection problems and for assessing the severity of ED. Patients with an IIEF score ≤21 underwent diagnostic test for the type of vascular insufficiency.
To establish the diagnosis of VED, penile color duplex Doppler ultrasonography was performed for all subjects. The assessment of penile vasculature was computed by measuring the inner diameter of cavernosal artery for all patients before and after intracavernosal injection with 20 lg of prostaglandin E1. Moreover, peak systolic velocity (PSV) and end-diastolic velocity were evaluated following prostaglandin E1 injection. The patients were observed for 1 h to assess the erectile response. Resistive index (RI) was calculated as (PSV-EDV)/PSV according to Golubinski and Sikorski (2002) . A PSV of >25 cm/s + EDV < 5 cm/s + RI > 0.8 is considered to prove normal erection; a PSV < 25 cm/ s + EDV < 5 cm/s + RI > 0.8 indicates inflow pathology; a PSV > 25 cm/s + EDV > 5 cm/s + RI < 0.8, venous leakage and a PSV < 25 cm/s + EDV > 5 cm/s + RI < 0.8, mixed vascular disorder. In addition to the obtained data on intimal thickness, PSV, EDV, and RI, the visual erection and tumescence (elongation, rigidity) provided a supplementary tool of verification.
Patients with any known predisposing risk factors for ED such as Peyronie's disease, anatomic abnormalities of the penis (fibrosis), thyroid dysfunction, other concomitant sexual dysfunction, including a history of pelvic surgery, history of severe hematological, renal or hepatic disease (including low urinary tract disorders), premature ejaculation, the use of any medication known to cause ED such as antihypertensive, antiandrogens, antidepressants, psychotropic drugs, and any substance abuse were excluded from the study. Accordingly, the present case-control study regrouped a total of 312 men: 164 unrelated patients with VED aged between 43 and 66 years and 148 healthy subjects aged between 40 and 67 years, without sexual malfunction and who did not have diabetes or a history of psychological, medical, or neurological diseases, including ED.
All participants gave consent prior to enrollment, and all procedures followed were approved by the responsible Medical Ethics Committee on human experimentation of the Hedi Cheker Hospital of Sfax.
Genetic analysis
DNA was extracted from peripheral blood leukocytes using the method of salting out (Miller et al., 1988) . Quality control of the DNA was verified photometrically. Determination of nucleotide changes was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique using the isolated genomic DNA.
For the detection of the eNOS T-786C, the following primers were used: 5 0 -GTG TAC CCC ACC TGC ATT CT-3 0 (sense) and 5 0 -CCC AGC AAG GAT GTA GTG AC-3 0 (anti-sense). DNA amplification was carried out for 35 cycles in the following conditions: denaturation at 94°C for 30 s, annealing at 62°C for 40 s, and extension at 72°C for 1 min. NaeI (New England Biolabs, Evry, France) restriction endonuclease digestion was then performed for 16 h at 37°C. The TT wild-type genotype has a size of 308 bp. The presence of C at nucleotide 786 allows cleavage of the 308 bp product into 227 bp and 81 bp fragments ( Fig. 2A ).
The primers used for the PCR amplification of the eNOS G894T were as follows: 5 0 -CAT GAG GCT CAG CCC CAG AAC-3 0 (sense) and 5 0 -AGT CAA TCC CTT TGG TGC TCA C-3 0 (antisense). Amplification conditions were the same as previously described with the annealing temperature at 68°C. Each PCR product was then digested with BanII restriction endonuclease (New England Biolabs). The undigested product (TT) has a size of 206 bp; complete digestion (GG wild-type genotype) results in bands of 124 and 82 bp (Fig. 2B ). PCR reactions were carried out for the GNB3 C825T using the primers 5 0 -TGC CAC CCG TGC CCT CAG TT-3 0 (sense) and 5 0 -GGC CCT TAC CCA CAC GCT CAG A-3 0 (anti-sense). DNA was amplified following the same conditions described for the eNOS G894T. The PCR products were detected following incubation with a restriction endonuclease (BtgI; New England Biolabs) overnight at 37°C. The TT mutant-type genotype has a size of 244 bp with undigested product. The CC wild-type allele has two bands of 143 bp and 101 bp (Fig. 2C ). Figure 1 Hypothetical interaction between the G-protein b3 subunit C825T polymorphism and eNOS polymorphisms leading to impaired penile erection. b3s, GNB3 C825T polymorphism; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; PGE1, prostaglandin E1; NA, noradrenaline; GPCR, G-proteincoupled receptor; ET-1, endothelin-1; ETB, endothelin receptor B (a classic GPCR); PI3-kinase, phosphatidylinositol 3-kinase; Akt, protein kinase B; PLC, phospholipase C; PIP2, phosphatidylinositol-4,5-bisphosphate; IP3, inositol trisphosphate, DAG, diacylglycerol; PKC, protein kinase C; MAPK, mitogen-activated protein kinases; GTP, guanosine triphosphate; ATP, adenosine triphosphate; cGMP, cyclic guanosine monophosphate; cATP, cyclic adenosine monophosphate; Ca2+, calcium; VSMCs, vascular smooth muscle cells; (+), activation; (À), inhibition. Produced with reference to Liu et al. (2003) ; Rosskopf et al. (2003) ; Liu et al. (2012 Liu et al. ( , 2014 . [Colour figure can be viewed at wileyonlinelibrary.com]
Laboratory analysis
Blood samples were collected following overnight fasting and were centrifuged immediately at 4°C at 3000 rpm for 10 min. The obtained plasma was used for the assessment of biochemical parameters. Fasting plasma glucose, lipid, and hepatic profiles were determined by automated analysis using the ADVIA 1800 Chemistry System apparatus. HbA1c was measured by the medical device BioRAD D-10 (REF: 220-0101, D-10 TM Hemoglobin A1C Reorder Pack). Insulin was quantified photometrically using an immunoenzymometric assay kits (REF.: IS 130D; Calbiotech). Serum hormones were assessed using assay kits from Abbott Laboratories (Chicago, IL, USA) on the Architect Abbott ci4100 analyzer.
Statistical analysis
Statistical analysis of clinical, biochemical, and sociodemographical characteristics was performed using SPSS version 18.0 statistical software (Inc, Chicago, IL). Epi InfoTM v.7 software was used to compare the distribution of alleles, genotypes, and other categorical variables. Fisher exact probability was used to test for association. The multiple comparison p-values were corrected by Bonferroni correction. Analysis of haplotypes was carried out by SNPStats web tool. A probability of the null hypothesis being correct lower than 5% was considered significant.
RESULTS
Characteristics of the study population
The clinical and biochemical characteristics of the ED patients and healthy controls are summarized in Table 1 . As a known risk factor for ED, age was matched between the two groups. The mean durations of diabetes and VED in the patients group were 10.52 AE 6.9 and 3.18 AE 2.6 years, respectively.
Fasting glucose, HbA1c, insulin, the Homeostatic Model Assessment of Insulin Resistance, urea, total cholesterol, triglycerides, LDL-cholesterol, and gamma GT plasma levels were significantly higher in VED patients than in controls, whereas AST, ALT, and direct bilirubin levels were lower. Thyroid and proerectile system hormones plasma analysis showed no differences between patients and healthy subjects.
Allelic and genotypic distribution
The distribution of genotype and allele frequencies of the studied polymorphisms within patient and control groups is presented in Table 2 . The genotypic frequencies of patients and controls were consistent with expectations under the Hardy-Weinberg equilibrium. The Bonferroni method was conducted to perform correction for multiple comparisons whereby the p value was multiplied with the number of comparisons (p corrected). It was considered to be significant when p values after Bonferroni correction (by 92) < 0.05. The p > 1 results from multiplying the original p-value with the number of tests.
Our results showed a significant association of the eNOS G894T and T-786C, but not of the GNB3 C825T gene polymorphisms with altered susceptibility to VED. After Bonferroni correction, the frequencies of heterozygous (GT) genotype of G894T and of CC homozygote minor genotype of T-786C polymorphism were still more prevalent in T2D patients than the controls and associated with an increased risk of VED. When the analysis is limited to individuals without dyslipidemia and cardiovascular disease (CVD), the risk of ED also holds for the G894T and T-786C eNOS gene polymorphisms (Table 3 ). To refine the heterogeneity of this disorder, we subdivided T2D participants into subgroups of patients with and without comorbidities (Table S1 ). When patients were stratified based upon CVD, it was noted that the mutant alleles of both eNOS variants G894T and T-786C are associated with a reduced risk of cardiovascular pathologies and hyperlipidemia among people with T2D. Similar associations were not reported in terms of obesity and hypertension (data not shown).
Models of inheritance
The genotypes with the T allele (GT+TT) of the G894T polymorphism statistically increase the risk of VED compared with the genotype GG (OR = 2.07, 95% CI = 1.31-3.25; p = 0.002) (Table 4) . Similarly, the recessive model (CC vs. TT+TC) of T-786C type revealed 3.5 times increased risk for VED within diabetic patients (OR = 3.66, 95% CI = 1.44-9.31; p = 0.004). Our results do not convey any significant association of the GNB3 C825T polymorphism with ED risk according to the tested models.
Haplotype analysis
There was a significant additive interaction between the genotypes of G894T and T-786C polymorphisms of the eNOS gene on the risk of VED (Table S2 ). All combined genotypes of the G894T and T-786C polymorphisms affected the predisposition to VED in T2D patients with most particularly the concomitant presence of the 894T and 786T alleles (OR = 2.41, 95% CI = 1.27-4.56; p = 0.007).
Secondary analysis
The distribution of genotype and allele frequencies of eNOS and GNB3 SNPs according to ED severity was assessed using multiple regression models. No significant associations were recorded between the IIEF-5 score and the risk of the three studied gene polymorphisms. Likewise, a significantly different onset of age of VED was not found between the genotypes for the studied gene polymorphisms.
DISCUSSION
Recently, several studies provided evidences that the GNB3 and eNOS gene polymorphisms are implicated in genetic susceptibility to ED (Wang et al., 2010; Safarinejad et al., 2013; Gao et al., 2017) . The present study is the first attempt to identify the association between the eNOS G894T, eNOS T-786C, and GNB3 C825T variants and VED risk in T2D North African subjects.
The eNOS G894T in the exon 7 and the T-786C in the promoter region are suggested to be functionally active in the transcriptional pathway (Safarinejad et al., 2011) . These two functional polymorphisms decrease NO production (the main chemical mediator and vasoactive neurotransmitter of penile erection process) and disturb eNOS activity (Seckin et al., 2016) . The present study shows a significant association of the eNOS G894T and T-786C polymorphisms with VED prevalence. Concerning the G894T variant, our results are in line with the findings of previous studies on the Taiwanese, Turkish, and Iranian populations (Lee et al., 2007; Erol et al., 2009; Safarinejad et al., 2011) . However, a study on the German population does not support a role of this polymorphism in the predisposition to risk of ED (Eisenhardt et al., 2010) . In addition, the 786C allele distribution in our study matches the results of two investigations carried out on the Turkish and Iranian population (Sinici et al., 2010; Safarinejad et al., 2011) , but it differs from the outcome of Meluz ın et al. (2009) who failed to find any relationship between this variant and the presence of ED in the Czech population. The disparities observed in these studies may be related to different patient ethnic backgrounds and variations in ED etiology. In fact, different ED models are used, such as neurogenic, vasculogenic, and aging, which means that what may work as a genetic marker in one model may not be applicable in another model. In addition, previous case-control studies investigated VED in populations with (Lee et al., 2008; Sinici et al., 2010; Safarinejad et al., 2013) and without (Safarinejad et al., 2011) metabolic disorders (such as diabetes, hyperlipidemia, and hypertension), which may further explain the discrepancy between the conducted studies. Accordingly, it is important to point out that the outcomes of the present work are only valid for diabetic patients.
In the present study, the combined effects of the eNOS gene T-786C TT genotype and G894T TT genotype increased the risk of VED. Our findings provide additional evidence that the genetic contribution to the pathogenesis of VED appears to be significant within patients with those variants. Investigating the mechanisms regulating the possible biological interactions of both eNOS polymorphisms will provide a comprehensive assessment of their genetic influence in modulating VED predisposition. Moreover, the genotype distribution of the heterozygous GT genotype of G894T and of homozygote CC minor allele genotype of T-786C suggests that these genotypes are associated with a high susceptibility to develop VED. Supporting our results, the heterozygote GT genotype was associated with an increased risk of ED in Asian populations (Liu et al., 2015) and similar distribution of the eNOS T-786C CC genotype with ED was reported in the Turkish population (Sinici et al., 2010) .
According to Kedzierska et al. (2006) , GNB3 gene polymorphisms affect some of known physiological pathways that are involved in the regulation of penile vasomotor tone. Although the GNB3 variant was considered as a predisposing risk factor for developing VED in Iranian males (Safarinejad et al., 2013) , no evidence for a significant association between this SNP and VED is observed in the present study. Other studies also failed to show an association of the C825T polymorphism with ED in the Taiwanese and German populations (Lee et al., 2008; Eisenhardt et al., 2010) . A possible explanation is that this SNP cannot affect GNB3 mRNA transcripts stability, as reported by Sun et al. (2005) . However, other published data suggest that the C825T variant increases differential G-protein activities (Kedzierska et al., 2006) . In another study, the GNB3 gene was associated with an increasing risk of IR (Siffert, 2005) . Recently, it has been proved that the severity of IR affects the NO-cGMP pathway leading to impaired NO bioactivity, changes in vascular tone and vascular smooth muscle cells function (Ben Khedher et al., 2017) . This finding suggests that the association between the C825T polymorphism and VED might not exactly be causative, but might be linked to increased risk of IR and downregulation of eNOS activity.
High-quality epidemiological trials reported that several risk factors are related to ED such as hypertension and CVD (Javaroni & Neves, 2012) . As almost half of our population study is exposed to such comorbidities, we assessed the association between gene polymorphisms and ED regardless these confounding factors. Our finding showed that VED risk also holds when comparing diabetic patients without vascular complications to the control group. This clearly demonstrates that there is a factor of genetic susceptibility to diabetic VED regardless the vascular complications. Furthermore, the present study showed Table 2 Genotypic and allelic distribution of the G894T, T-786C, and C825T polymorphisms in the studied cohort that among T2D patients, the T recessive allele carriership and C recessive allele carriership of eNOS gene polymorphisms have a reduced risk of developing CVD and dyslipidemia. The role of eNOS gene polymorphisms in the incidence of metabolic abnormalities seems to vary according to the studied population. Our data suggest that the association between mutations in the eNOS gene and increased risk for metabolic disorders remains to be proved.
Therapeutic strategies
There is a growing interest to develop new therapeutic strategies for the treatment of ED in people with genetically altered cells. Gene and stem cell therapy interventions to restore eNOS expression and subsequent endothelial function present a possible strategy. It is also suggested that the utility of administration of inhaled NO as a treatment for patients with such dysfunction should be evaluated. The use of soluble guanylyl cyclase stimulators to increase cGMP independently of NO is another possible alternative. Regarding the GNB3 C825T polymorphism, it may be beneficial to stabilize Gb3s expression concomitant with stimulation with b-agonist therapy ligands.
Limitations
There are limitations of the present study. The sample size is adequate for statistical analysis in case-control studies, but not large enough for epidemiological considerations. Therefore, the present data should be considered as preliminary and future multicenter studies with a large population size are recommended. As functional analysis gives a better comprehensive assessment in SNPs association studies, the measurement of eNOS activity should be considered in future investigations.
CONCLUSIONS
This study shows significant association between VED and mutant-allele carriers of eNOS gene in a T2D Tunisian population and supports an active role of these gene polymorphisms in the development and/or progression of VED in diabetic patients. The genetic susceptibility to develop VED in diabetic men should broadly be investigated and further studies should consider the development of new approaches and personalized medical application in the treatment of patients with similar genetic predisposition.
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